Ipsen: raises annual targets
(CercleFinance.com) - On unveiling its H1 results, Ipsen has raised its targets for 2024, now expecting sales growth of over 7% at constant exchange rates, and an operating margin from activities in excess of 30%.
The pharmaceutical company's H1 net income from activities rose 1.6% to E399.4m, for an operating margin from activities that fell 1.6 point to 32.4%.
Sales rose by 8% to E1.66bn (+9.5% at constant exchange rates), driven by the performance of Cabometyx and Dysport, as well as contributions from Bylvay and Onivyde.
In addition, Ipsen has signed a global partnership agreement outside the US with Day One Biopharmaceuticals for tovorafenib in GBG, the most common form of pediatric brain cancer, and any future indications developed by Day One.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The pharmaceutical company's H1 net income from activities rose 1.6% to E399.4m, for an operating margin from activities that fell 1.6 point to 32.4%.
Sales rose by 8% to E1.66bn (+9.5% at constant exchange rates), driven by the performance of Cabometyx and Dysport, as well as contributions from Bylvay and Onivyde.
In addition, Ipsen has signed a global partnership agreement outside the US with Day One Biopharmaceuticals for tovorafenib in GBG, the most common form of pediatric brain cancer, and any future indications developed by Day One.
Copyright (c) 2024 CercleFinance.com. All rights reserved.